For more than 60 years, this blank slate approach has been the Food and Drug Administration’s gold standard — and for good ...

In the first of a two-parter, lawyers at Santarelli analyse the patentability of therapeutic inventions where publication of ...

Certain low-risk or mature devices may see reduced trial requirements, but the broader trend is toward augmenting—not ...

Charlie Paterson, partner at PA Consulting, outlines how limited FDA guidance on innovative designs, decentralized models, and digital endpoints is forcing clinical operations teams to recalibrate ...

Researchers at Mount Sinai launch a new AI platform to match more cancer patients with clinical trials, aiming to expand ...

SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports that an analyst research report was published on the Company that explains ...